News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Cardinal Health Launches Navista™ TS to Help Oncology Practices Improve Patient Care, Lower Costs and Drive Success in Value-Based Care
04/07/2021

DUBLIN, Ohio, April 7, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care. 

"Community-based oncology practices are facing unprecedented pressure as they pivot to adapt to value-based reimbursement models," said Heidi Hunter, President of Cardinal Health Specialty Solutions. "With Navista™ TS, we are delivering the most complete set of integrated, AI-enabled solutions and actionable insights to enable oncologists to improve patient care and enhance practice performance."

Navista™ TS is comprised of connected, point-of-service technology solutions including:

  • Episode Analytics, a data-driven cost tracking tool, developed by Cardinal Health's innovation engine, Fuse. This tool enables oncologists and administrators to accurately measure the cost of care at the start of and during the episode of care, allowing for more informed treatment decisions and clearer insights into value-based performance.
  • CureMD Oncology Cloud. The integrated platform includes electronic health records (EHR), a practice management system (PMS), revenue cycle management services (RCM), a patient portal and telehealth solutions. The platform helps to simplify decision making, streamline operations and ensure a smooth transition to value-based care, saving providers time and reducing administrative burden so they can focus on patient care. CureMD and Cardinal Health will work collaboratively to provide CureMD's oncology tech solutions.
  • AI-enabled population health decision support, CORE™, by Jvion. CORE™ helps oncologists to proactively identify patients who are at, or on an accelerated path to becoming, high-risk of adverse events. The CORE surfaces the clinical and socioeconomic levers and interventions to deploy to avoid costly ER and hospital visits. Cardinal Health is the exclusive reseller of Jvion oncology products to community oncology practices.
  • Clinical trials matching solution, VIPER™, by Deep Lens. VIPER™ uses AI to identify and match cancer patients to clinical trials, including precision medicine studies, faster and more efficiently. Cardinal Health and Deep Lens are working in collaboration to deliver VIPER™ to community oncology practices.

Through this comprehensive suite of solutions, Navista™ TS helps oncology practices understand the biggest cost and value drivers, identify treatments that offer the highest-quality care at the lowest cost, and select the right care plan at the onset of treatment. It also helps to automate manual processes and reduce administrative burdens.

Navista™ TS may be used together as an integrated suite or as standalone tools. For more information, visit www.cardinalhealth.com/navista.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Contacts
Marcia Frederick, marcia.frederick@cardinalhealth.com and (614) 757-9968; Investors: Kevin Moran, kevin.moran@cardinalhealth.com and (614) 757-7942.

 

SOURCE Cardinal Health

More Company News
08/11/2022

-- Mike Kaufmann to Step Down as Chief Executive Officer and from Board of Directors -- -- Jason Hollar, Chief Financial Officer, Named Chief Executive Officer -- -- Patricia English to Serve as...

08/01/2022

Greene previously served as SVP of EIT for the company's Pharmaceutical Segment DUBLIN, Ohio, Aug. 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that Michelle Greene has been...

07/22/2022

TO: ALL PERSONS AND ENTITIES THAT HELD CARDINAL HEALTH, INC. COMMON STOCK AS OF THE CLOSE OF TRADING ON MAY 25, 2022 AND THAT CONTINUE TO HOLD CARDINAL HEALTH COMMON STOCK AS OF THE CLOSE OF...

07/06/2022

Strengthening Cornerstone Rheumatology™ GPO as a leading rheumatology-focused GPO by providing innovative solutions and robust specialty drug access to over 1,300 rheumatology providers nationwide.

View all company news »

* Required Fields